Black Reishi

G. sinense (Black Reishi) is classified in the same pharmacopoeial category as G. lucidum in Chinese medicine. G. sinense extracts inhibit platelet aggregation via prostaglandin pathways (as described for related ganodermic acids), reduce ADP-induced aggregation, and may also inhibit CYP2C9-mediated warfarin metabolism. A clinical case report demonstrated INR elevation to 6.92 and 8.22 in a hemodialysis patient after ingesting G. lucidum extracts (same official category), with values returning to normal after cessation.

Exercise extreme caution. Monitor INR closely in all patients on warfarin who use G. sinense supplements. Advise patients to disclose Ganoderma supplement use to their anticoagulation clinic. Discontinue G. sinense at least 2 weeks before surgery. Consider alternative or closer INR monitoring schedule (weekly vs monthly).

Ganoderic acid A (GAA), a major triterpene found in Ganoderma sinense, inhibits CYP3A4 in a time-dependent, concentration-dependent manner (IC50 = 15.05 µM; KI/Kinact = 7.91/0.048 µM/min). GAA is a non-competitive inhibitor of CYP3A4 and a mechanism-based inhibitor, meaning inhibition can persist after cessation. Plasma levels of CYP3A4 substrates may be significantly elevated.

Closely monitor drug levels and clinical response when G. sinense is used alongside CYP3A4 substrates with narrow therapeutic indices (tacrolimus, cyclosporine, midazolam, irinotecan). Anticipate increased drug exposure (higher AUC). Reduce substrate doses if toxicity is observed.

Ganoderic acid A competitively inhibits CYP2D6 with IC50 = 21.83 µM and Ki = 10.07 µM in human liver microsomes. This inhibition may reduce metabolism of CYP2D6 substrates, leading to elevated plasma levels. Codeine (a CYP2D6 prodrug) may have reduced analgesic activation; other substrates (metoprolol, haloperidol) may reach toxic levels.

Monitor for CYP2D6 substrate toxicity (e.g., excessive beta-blockade from metoprolol, QTc prolongation from haloperidol). For codeine-dependent patients, be aware that analgesic effect may vary. Consider alternative analgesics in patients taking G. sinense.

G. sinense polysaccharides enhance immune function by activating macrophages, NK cells, and T-lymphocytes, similar to G. lucidum. These immunomodulatory effects may counteract the intended immunosuppressive action of drugs used in transplant medicine or autoimmune disease management.

Avoid G. sinense in organ transplant recipients and patients with autoimmune conditions requiring immunosuppression. Monitor drug trough levels (cyclosporine, tacrolimus) if supplement use is identified.

G. sinense contains triterpenoids and polysaccharides with hypoglycemic activity analogous to G. lucidum. In animal studies, G. lucidum polysaccharides inhibit gluconeogenesis (GP, FBPase, PEPCK, G6Pase) and improve insulin sensitivity. Combined use with antidiabetic agents may produce additive glucose lowering and hypoglycaemia risk.

Monitor blood glucose levels in patients combining G. sinense with antidiabetic medications. Particular care is needed with insulin and sulfonylureas. Educate patients about hypoglycaemia warning signs. Adjust antidiabetic doses if blood glucose consistently falls below target.